Similar articles

• Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector.

  Reddy PS, Sakhuja K, Ganesh S, Yang L, Kayda D, Brann T, Pattison S, Golightly D, Idamakanti N, Pinkstaff A, Kaloss M, Barjot C, Chamberlain JS, Kaleko M, Connelly S. Reddy PS, et al. Mol Ther. 2002 Jan;5(1):63-73. doi: 10.1006/mthe.2001.0510. Mol Ther. 2002. PMID: 11786047
• Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero.

  Lipshutz GS, Sarkar R, Flebbe-Rehwaldt L, Kazazian H, Gaensler KM. Lipshutz GS, et al. Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13324-9. doi: 10.1073/pnas.96.23.13324. Proc Natl Acad Sci U S A. 1999. PMID: 10557319 Free PMC article.
• Preclinical gene therapy studies for hemophilia using adenoviral vectors.

  Thorrez L, VandenDriessche T, Collen D, Chuah MK. Thorrez L, et al. Semin Thromb Hemost. 2004 Apr;30(2):173-83. doi: 10.1055/s-2004-825631. Semin Thromb Hemost. 2004. PMID: 15118929 Review.
• Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes.

  Kay MA, Graham F, Leland F, Woo SL. Kay MA, et al. Hepatology. 1995 Mar;21(3):815-9. Hepatology. 1995. PMID: 7875680
• Improved adenoviral vectors: cautious optimism for gene therapy.

  Channon KM, George SE. Channon KM, et al. QJM. 1997 Feb;90(2):105-9. doi: 10.1093/qjmed/90.2.105. QJM. 1997. PMID: 9068800 Review. No abstract available.